Huang Hongyun, Chen Lin, Chopp Michael, Young Wise, Robert Bach John, He Xijing, Sarnowaska Anna, Xue Mengzhou, Chunhua Zhao Robert, Shetty Ashok, Siniscalco Dario, Guo Xiaoling, Khoshnevisan Alireza, Hawamdeh Ziad
Beijing Hongtianji Neuroscience Academy, Beijing, 100143, China.
Department of Neurosurgery, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine Beijing, Beijing, 100007, China.
J Neurorestoratology. 2021 Mar 5;9(1):1-12. doi: 10.26599/JNR.2021.9040002. Epub 2022 May 10.
COVID-19 has been an emerging and rapidly evolving risk to people of the world in 2020. Facing this dangerous situation, many colleagues in Neurorestoratology did their best to avoid infection if themselves and their patients, and continued their work in the research areas described in the . Neurorestorative achievements and progress during 2020 includes recent findings on the pathogenesis of neurological diseases, neurorestorative mechanisms and clinical therapeutic achievements. Therapeutic progress during this year included advances in cell therapies, neurostimulation/neuromodulation, brain-computer interface (BCI), and pharmaceutical neurorestorative therapies, which improved neurological functions and quality of life for patients. Four clinical guidelines or standards of Neurorestoratology were published in 2020. Milestone examples include: 1) a multicenter randomized, double-blind, placebo-controlled study of olfactory ensheathing cell treatment of chronic stroke showed functional improvements; 2) patients after transhumeral amputation experienced increased sensory acuity and had improved effectiveness in work and other activities of daily life using a prosthesis; 3) a patient with amyotrophic lateral sclerosis used a steady-state visual evoked potential (SSVEP)-based BCI to achieve accurate and speedy computer input; 4) a patient with complete chronic spinal cord injury recovered both motor function and touch sensation with a BCI and restored ability to detect objects by touch and several sensorimotor functions. We hope these achievements motivate and encourage other scientists and physicians to increase neurorestorative research and its therapeutic applications.
2020年,新型冠状病毒肺炎(COVID-19)已成为全球人类面临的一种新出现且迅速演变的风险。面对这一危险形势,神经修复学领域的许多同仁竭尽全力保护自己和患者免受感染,并在本文所述的研究领域继续开展工作。2020年神经修复学的成果与进展包括神经疾病发病机制、神经修复机制及临床治疗成果的最新发现。今年的治疗进展包括细胞治疗、神经刺激/神经调节、脑机接口(BCI)和药物神经修复治疗等方面的进展,这些进展改善了患者的神经功能和生活质量。2020年发布了四项神经修复学临床指南或标准。里程碑式的例子包括:1)一项关于嗅鞘细胞治疗慢性中风的多中心随机、双盲、安慰剂对照研究显示功能有所改善;2)经肱骨截肢后的患者感觉敏锐度提高,使用假肢在工作和其他日常生活活动中的有效性得到改善;3)一名肌萎缩侧索硬化症患者使用基于稳态视觉诱发电位(SSVEP)的脑机接口实现了准确快速的计算机输入;4)一名完全性慢性脊髓损伤患者通过脑机接口恢复了运动功能和触觉,并恢复了通过触摸检测物体的能力和一些感觉运动功能。我们希望这些成就能够激励和鼓励其他科学家和医生加强神经修复研究及其治疗应用。